The 4th annual
Cancer Vaccines conference will strengthen knowledge of targeted immunotherapies taking the foreground in revolutionizing cancer vaccines as well as look at the practicalities towards achieving sustained immune response.
Understanding personalized cancer treatment will be a major focus, as will hearing from a selection of biotechs and industry pioneers at the forefront of vaccine development.
We have worked closely with a leading panel of experts such as GSK Vaccines, Vaccinogen, The National Cancer Institute and Kings College London, to create a programme that will expand scientific horizons in topics such as formulation development, tumour genetic heterogeneity, fully personalised cancer treatment, combination therapies, gene editing for immunotherapy, plus much more!
Reasons to Attend:
- Address the provocative issue of tumour genetic heterogeneity in immunotherapy
- Understand the angiogenic process in both normal and tumour and development
- Gain key industry perspective in combination therapies to advance immune-oncology vaccines and enhance patient outcomes
- Envision RNA - vaccinology for building the next-generation of RNA immunogens
- Immerse yourself into a universe of new insights as we explore cutting edge developments in areas such as CAR T-Cell Therapy, Oncolytic viral therapies, Gene-therapy and Adoptive T-Cell transfer
Plus 2 Interactive Pre-Conference Workshops | Tuesday 15th September 2015
Workshop A: Stress is Good: Heat Shock Protein 70 as a Next-Generation Theranostic with Broad Applicability in Oncology
Workshop Leaders: Alan Graham Pockley, 1Associate Director & Professor of Immunobiology, 2CEO, 3Founder and CEO 1Nottingham Trent University, 2Multimmune GmbH, 3Chromocyte Ltd, UK and
Dr. Gabriele Multhoff, 1University Professor in Experimentelle Radioonkologie und Strahlenbiologie, 2Group Leader, 1Technische Universität München, 1Helmholz Zentrum München
8.30am - 12.30pm
Workshop B: Tumour Genomic Heterogeneity in Immunotherapeutics
Workshop Leaders: Michael G. Hanna, Jr. Founder & Chairman Emeritus, Vaccinogen, Inc.
1.30pm - 5.30pm
Speakers
- Alan Graham Pockley, Associate Director & Professor of Immunobiology, Nottingham Trent University
- Aymen Al-Shamkhani, Professor in Immunology, University Of Southampton
- Dr. Ravi Madan, National Cancer Institute
- Eric Leire, CEO, DanDrit Biotech
- Erik Ramos, manager, Northwest Biotherapeutics
- Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
- Felipe Bedoya, Director Product Development Laboratory, University Of Pennsylvania
- Hardev Pandha, Director and Physician of Medical Oncology, Director of Surrey Cancer Research Institute, University of Surrey
- John Maudsley, CEO, Cancer Vaccines Ltd
- Linda F. Powers, Chair and CEO, Northwest Biotherapeutics
- Michael G. Hanna, Jr., Founder & Chairman Emeritus, Vaccinogen, Inc.
- Professor Dr. Dirk Jager, Director Medical Oncology, National Center for Tumour Diseases, University Medical Centre
- Sebastian Kreiter, VP Immunotherapy, BioNTech RNA Pharmaceuticals
- Stephanie McArdle, Senior Research Scientist, The John van Geest Cancer Research Centre, Nottingham Trent University
- Thomas Felzmann, CEO, Activartis Biotech GmbH
- Ugo D'oro, Unit Head Immunology, GSK Vaccines
- Vaios Karanikas, Biomarker Experimental Medicine Leader, Tumour Immunology, Roche Innovation Center Zurich
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Who Should Attend
This conference is ideal for professionals involved in the following areas:
- Cancer Immunotherapeutics
- Vaccine developement
- Clinical Trials
- RNA-based vaccine development
- Vaccine delivery systems
- Angionesis
Venue
Marriott Hotel, Regents Park128 King Henry's Road
London, NW3 3ST
United Kingdom
